July 19, 2018
Targeting Lung Cancer in Rare Disease Patient Populations
SOMERVILLE, MA— June 19, 2018 — Andarix Pharmaceuticals, a clinical stage company aimed at developing targeted peptide therapies for hard to treat cancers, announced today that its Chief Executive Officer, Chris Adams, will present at the Rare Disease Innovation Summit set to take place in Cambridge, MA June 19-20.
The Rare Disease Innovation conference gives Andarix the opportunity to presents its clinical findings on Tozaride, in front of an audience which shares the common goal of seeking innovative therapies for the treatment of rare diseases.
About Tozaride
Tozaride is a novel, best-in-class cancer therapy based on a radio-labeled somatostatin peptide analogue. Early clinical studies of Tozaride demonstrated that it is well tolerated and may produce prolonged stable disease and improved overall survival in advanced lung cancer patients whose disease has continued to progress after failing other therapies. Tozaride targeted radiotherapy represents a new treatment paradigm which is expected to yield significant clinical benefit for both lung cancer (SCLC, NSCLC), and pancreatic cancer patients. Along with its companion diagnostic that helps identify patients most likely to respond – those with enough expression of the peptide’s target – Tozaride could provide another treatment option for patients who are not eligible for, or who have not responded to current therapies.
About Andarix Pharmaceuticals
Andarix Pharmaceuticals is at the forefront of personalized therapies for cancer, developing both the imaging agents that can identify appropriate patients, as well as the targeted therapies for these patients. The company’s products have progressed through early clinical development. The Andarix technology is based on a proprietary somatostatin peptide conjugate applicable to lung, pancreatic, neuroendocrine, and other cancers. Extensive research has demonstrated that somatostatin receptors are
highly up-regulated on several solid tumors, particularly lung, neuroendocrine, and pancreatic tumors. To learn more about Andarix, please visit www.andarix.com.
Contact:
Andarix Pharmaceuticals
617-957-9858
info@andarix.com